ARKG250502P16500
- 0.49
- 0.000.00%
ARK Genomic Revolution ETF Newsroom
SA Asks: What Are the Best Quantum Computing Stocks?
What's Next: Twist Bioscience's Earnings Preview
Catalyst Watch: Powell Presser, AMD Earnings, IBM Event, and Lions Gate Splits in Two
Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results
Recursion Pharmaceuticals Q1 2025 Earnings Preview
12 Health Care Stocks Moving In Friday's Intraday Session
Adaptive Biotechnologies Analyst Ratings
SA Analyst Downgrades: AAPL, SMCI, MRNA, TRIP, IIPR, STLA, TWST
Peering Into Natera's Recent Short Interest
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Adaptive Biotechnologies Shares Are Trading Higher After the Company Reported Q1 Financial Results and Beat Its EPS and Revenue Estimates.
Jim Cramer: Sunrun Had 'Bad Couple Of Quarters,' ExlService Holdings Is 'Solid'
Earnings Call Summary | Adaptive Biotechnologies(ADPT.US) Q1 2025 Earnings Conference
Adaptive Biotechnologies Targets 30% MRD Volume Growth in 2025 With Raised Guidance
Cathie Wood Pours $9.8 Million In Robinhood Despite Crypto Revenue Slump, Keeps Dumping Palantir Ahead Of Earnings
Stifel Maintains Buy on Guardant Health, Raises Price Target to $60
How Do Investors Really Feel About Recursion Pharmaceuticals?
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $60
10 Stocks Defying Wall Street Turbulence to Kick off the Month of May
UBS Maintains Buy on Guardant Health, Raises Price Target to $70